NASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis $3.14 +0.03 (+0.96%) Closing price 02:54 PM EasternExtended Trading$3.14 0.00 (0.00%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Larimar Therapeutics Stock (NASDAQ:LRMR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Larimar Therapeutics alerts:Sign Up Key Stats Today's Range$3.06▼$3.2250-Day Range$1.79▼$3.2552-Week Range$1.61▼$11.20Volume516,004 shsAverage Volume837,345 shsMarket Capitalization$201.05 millionP/E RatioN/ADividend YieldN/APrice Target$18.50Consensus RatingBuy Company Overview Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. Read More Larimar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreLRMR MarketRank™: Larimar Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 743rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Larimar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Larimar Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.61% of the float of Larimar Therapeutics has been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Larimar Therapeutics has recently increased by 1.88%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.61% of the float of Larimar Therapeutics has been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Larimar Therapeutics has recently increased by 1.88%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.64 News SentimentLarimar Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Larimar Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 10 people have searched for LRMR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 16 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Larimar Therapeutics' insider trading history. Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LRMR Stock News HeadlinesWedbush Research Analysts Reduce Earnings Estimates for LRMRJune 28, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for LRMR FY2025 EarningsJune 27, 2025 | americanbankingnews.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 3 at 2:00 AM | Brownstone Research (Ad)Research Analysts Issue Forecasts for LRMR Q2 EarningsJune 27, 2025 | americanbankingnews.comWedbush Lowers Larimar Therapeutics (NASDAQ:LRMR) Price Target to $15.00June 26, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Larimar Therapeutics (LRMR)June 24, 2025 | theglobeandmail.comLarimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia ProgramJune 23, 2025 | globenewswire.comLarimar Therapeutics to Host Conference Call on Regulatory Updates for Nomlabofusp Clinical Development ProgramJune 22, 2025 | nasdaq.comSee More Headlines LRMR Stock Analysis - Frequently Asked Questions How have LRMR shares performed this year? Larimar Therapeutics' stock was trading at $3.87 at the beginning of 2025. Since then, LRMR stock has decreased by 18.9% and is now trading at $3.14. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) released its earnings results on Wednesday, April, 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.04. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Larimar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Larimar Therapeutics investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings4/30/2025Today7/03/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LRMR CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$18.50 High Stock Price Target$26.00 Low Stock Price Target$10.00 Potential Upside/Downside+489.2%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.48% Return on Assets-46.08% Debt Debt-to-Equity RatioN/A Current Ratio7.48 Quick Ratio7.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.69 per share Price / Book1.17Miscellaneous Outstanding Shares64,030,000Free Float61,147,000Market Cap$201.05 million OptionableOptionable Beta0.86 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:LRMR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.